activated recombinant human factor VII
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Bleeding Disorder
Conditions
Acquired Bleeding Disorder, Trauma
Trial Timeline
Oct 6, 2004 → Nov 23, 2005
NCT ID
NCT00124293About activated recombinant human factor VII
activated recombinant human factor VII is a pre-clinical stage product being developed by Novo Nordisk for Acquired Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00124293. Target conditions include Acquired Bleeding Disorder, Trauma.
What happened to similar drugs?
4 of 20 similar drugs in Acquired Bleeding Disorder were approved
Approved (4) Terminated (4) Active (13)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01312636 | Pre-clinical | Completed |
| NCT01285089 | Pre-clinical | Completed |
| NCT01220141 | Pre-clinical | Completed |
| NCT01234545 | Pre-clinical | Completed |
| NCT00853086 | Pre-clinical | Completed |
| NCT00323570 | Phase 3 | Withdrawn |
| NCT01562457 | Phase 1 | Completed |
| NCT00123591 | Phase 2 | Completed |
| NCT00124293 | Pre-clinical | Completed |
| NCT00154427 | Phase 2 | Terminated |
| NCT00104455 | Phase 1 | Completed |
| NCT00154492 | Phase 2 | Completed |
| NCT00108758 | Phase 2 | Completed |
| NCT01476423 | Pre-clinical | Completed |
| NCT00571584 | Approved | Completed |
| NCT00426803 | Phase 2 | Completed |
| NCT01561352 | Phase 2 | Completed |
Competing Products
20 competing products in Acquired Bleeding Disorder